# US 2019/0314497 A1 · Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314497 A1
- Document ID: US20190314497A1
- Status: Published application
- Kind: A1
- Application number: 16/394,097
- Filed: 2019-04-25
- Published: 2019-10-17
- Earliest claimed: 2014-09-19
- Assignees: Pulmotect, Inc.; Board of Regents, The University of Texas System; Baylor College of Medicine
- Applicants: Pulmotect, Inc.; Board of Regents, the University of Texas System; Baylor College of Medicine
- Inventors: Burton DICKEY; Scott EVANS; Brian Gilbert; Diane Markesich; Brenton Scott; Michael TUVIM
- Web page: https://patentgrep.com/patent/US20190314497A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 31/215: of carboxylic acids
- A61K 31/24: having an amino or nitro group
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 38/05: Dipeptides
- A61K 38/06: Tripeptides
- A61K 38/07: Tetrapeptides
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Embodiments are directed to compositions and methods for treating viral infections.

## Claims

### Claim 1

A composition comprising: (a) PAM2CSK4lipopeptide, (b) immune stimulatory Toll-Like Receptor 9 (TLR) agonist oligodeoxy nucleotide, and (c) antiviral pharmaceutical, selected from nucleotide or nucleoside analogs, sialidase inhibitor, or protease inhibitor.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The composition of claim 1, wherein the immune stimulatory oligodeoxynucleotide is a type C oligodeoxynucleotide (ODN).

### Claim 4 (depends on 3)

The composition of claim 3, wherein the immune stimulatory oligodeoxynucleotide is ODN2395 or ODNM362 or ODN10101.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein the composition is formulated for administration to the lungs.

### Claim 7 (depends on 1)

A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition of claim 1 to an individual that has or is at risk of viral infection.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject has been exposed to a virus.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 7)

The method of claim 7, wherein the composition is administered by nebulization.

### Claim 12

(canceled)

### Claim 13

A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition comprising an aerosolized (a) PAM2CSK4lipopeptide and (b) immune stimulatory Toll-Like Receptor 9 (TLR) agonist oligodeoxy nucleotide in combination with an orally administered composition comprising an anti-viral pharmaceutical to an individual that has or is at risk of viral infection.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The method of claim 13, wherein the immune stimulatory oligodeoxynucleotide is a type C oligodeoxynucleotide (ODN).

### Claim 16 (depends on 13)

The method of claim 13, wherein the immune stimulatory oligodeoxynucleotide is ODN2395 or ODNM362 or ODN10101.

### Claim 17 (depends on 13)

The method of claim 13, wherein the antiviral pharmaceutical is a nucleotide or nucleoside analogs, sialidase inhibitor, or protease inhibitor.

### Claim at position 18

-25. (canceled)
